Can a stronger eylea dose cut eye injections in half?

NCT ID NCT07390253

Ongoing Disease control Sponsor: Vienna Institute for Research in Ocular Surgery Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether switching wet AMD patients who don't respond well to the standard 2mg dose of aflibercept (Eylea) to a higher 8mg dose can extend the time between injections while keeping vision stable. Fifty adults who have already had at least four 2mg injections will receive the higher dose and be followed for 12 months. The goal is to see if fewer injections are needed without losing vision benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept (8 mg injection)
What this could lead to: If successful, this could allow wet AMD patients to go longer between eye injections while keeping their vision stable.
What could go wrong: This is a small, early-phase study with only 50 participants. The higher dose may not work better or could cause more side effects like eye inflammation or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Vienna Institute for Research in Ocular Surgery

Vienna, 1140, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.